Communiqués Immuneering Corporation

Actions

IMRX

US45254E1073

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
4,480 ^USD	+0,45%		+4,92%	-31,91%

26/08	Immuneering annonce l'approbation par la FDA d'un nouveau traitement de deuxième ligne pour le cancer du pancréas métastatique et fait le point sur l'essai de phase 3 MAPKeeper 301 de l'atebimetinib	CI
06/08	Immuneering Corporation : HC Wainwright maintient sa recommandation à l'achat	ZM

Communiqués

10/09	Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival	GL
10/09	Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival	AQ
03/09	Immuneering to Participate in Upcoming Investor Conferences	GL
27/08	Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients	AQ
26/08	Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients	GL
05/08	Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates	GL
21/07	Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition	GL
17/07	Immuneering Corporation Announces Grants of Inducement Awards	GL
15/06	Immuneering Appoints Andrew Gengos as Chief Financial Officer	GL
11/06	Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer	GL
01/06	Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO	GL
21/05	Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy	GL
15/05	Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates	GL
21/04	Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting	GL
20/04	Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond	GL
06/04	Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference	GL
17/03	Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival	GL
06/03	Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates	GL
02/03	Immuneering to Present at the Leerink Global Healthcare Conference	GL
02/03	Immuneering to Present at the Leerink Global Healthcare Conference	AQ
18/02	Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	GL
07/01	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP	GL
23/12	Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026	GL
17/12	Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA	GL
17/12	Immuneering to be added to the Nasdaq Biotechnology Index	AQ